Eli Lilly Shares Are Trading Higher After the Company Announced Results From the SURMOUNT-1 Three-year Study of Tirzepatide, Showing That Weekly Tirzepatide Injections Reduced the Risk of Progression to Type 2 Diabetes by 94% in Adults With Pre-diabetes and Obesity.
海量资讯、精准解读，尽在新浪财经APP
VIP课程推荐
加载中...
APP专享直播
热门推荐
收起
新浪财经公众号
24小时滚动播报最新的财经资讯和视频，更多粉丝福利扫描二维码关注（sinafinance）
